**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 44950**

**Manuscript Type: ORIGINAL ARTICLE**

***Observational Study***

**Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis**

Zhong HJ *et al.* Cirrhosis, more than one disease state

Hao-Jie Zhong, Huan-Huan Sun, Lan-Feng Xue, Eileen M McGowan, Yu Chen

**Hao-Jie Zhong, Lan-Feng Xue, Yu Chen,** Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510000, Guangdong Province, China

**Hao-Jie Zhong,** Department of Gastroenterology, Guangdong Medical University, Zhanjiang 524000, Guangdong Province, China

**Huan-Huan Sun,** Department of Gastroenterology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an 710000, Shaanxi Province, China

**Eileen M McGowan,** Faculty of Science,University of Technology Sydney, Sydney NSW 2007, Australia

**ORCID number:** Hao-Jie Zhong (0000-0001-6586-756X); Huan-Huan Sun (0000-0002-7762-3260); Lan-Feng Xue (0000-0002-8175-6453); Eileen M McGowan (0000-0001-6371-3751); Yu Chen (0000-0003-0747-3479).

**Author contributions:** Zhong HJ, Sun HH, and Chen Y contributed to study conception and design; Zhong HJ, Sun HH, Xue LF, McGowan EM, and Chen Y contributed to data acquisition, data analysis and interpretation, and writing of the article; Zhong HJ, McGowan EM, and Chen Y contributed to editing, reviewing, and final approval of the article.

**Supported by** the Science and Technology Planning Project of Guangdong Province, No. 2015A030302085 and No. 2016A020212022.

**Institutional review board statement:** The study was reviewed and approved by the Ethical Committee of the First Affiliated Hospital of Guangdong Pharmaceutical University (2018-72).

**Informed consent statement:** Informed consent was waived by the Ethical Committee of the First Affiliated Hospital of Guangdong Pharmaceutical University.

**Conflict-of-interest statement:** There are no conflicts of interest for any of the authors.

**Data sharing statement:** The original anonymous dataset is available on request from the corresponding author at yuchen@gdpu.edu.cn.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Yu Chen, MD, PhD, Doctor,** Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19, Nonglinxia Road, Guangzhou 510000, Guangdong Province, China. yuchen@gdpu.edu.cn

**Fax:** +86-020-61325957

**Received:** December 7, 2018

**Peer-review started:** December 9, 2018

**First decision:** December 28, 2018

**Revised:** January 3, 2019

**Accepted:** January 9, 2019

**Article in press:** January 9, 2019

**Published online:** January 21, 2019

**Abstract**

***BACKGROUND***

Cirrhosis is a chronic late stage liver disease associated with hepatitis viruses, alcoholism, and metabolic disorders, such as Wilson disease (WD). There are no clear markers or clinical features that define cirrhosis originating from these disparate origins. We hypothesized that cirrhosis is not one disease and cirrhosis of different etiology may have differential clinical hepatic features.

***AIM***

To delineate the liver features between WD-associated cirrhosis and hepatitis B-associated cirrhosis in the Chinese population.

***METHODS***

In this observational study, we reviewed the medical data of consecutive inpatients who had WD-associated cirrhosis or hepatitis B-associated cirrhosis from January 2010 to August 2018, and excluded patients who had carcinoma, severe heart or pulmonary diseases, or other liver diseases. According to the etiology of cirrhosis, patients were divided into two groups: WD-associated cirrhosis group (60 patients) and hepatitis B-associated cirrhosis group (56 patients). The liver fibrosis degree, liver function indices, and portal hypertension features of these patients were compared between the two groups.

***RESULTS***

No inter-group differences were observed in the diagnostic liver fibrosis markers, however, clinical features clearly defined the origin of cirrhosis. WD-associated cirrhosis patients (16-29 years) had lower levels of alanine transaminase, aspartate transaminase, and bilirubin, lower prothrombin time, lower incidence of hepatic encephalopathy, and lower portal vein diameter (*P* ˂ 0.05), compared to cirrhosis resulting from hepatitis B in older patients (45-62 years). Importantly, they had decreased risks of progression from Child-Pugh grade A to B (odds ratio = 0.046, 95% confidence interval: 0.006-0.387, *P* = 0.005) and of ascites (odds ratio = 0.08, 95% confidence interval: 0.01-0.48, *P* = 0.005). Conversely, WD-associated cirrhosis patients had a higher risk of splenomegaly (odds ratio = 4.15, 95% confidence interval: 1.38-12.45, *P* = 0.011).

***CONCLUSION***

WD-associated cirrhosis presents a higher risk of splenomegaly associated with leukopenia and thrombocytopenia, although revealing milder liver dysfunction and portal hypertension symptoms, which recommends WD patients to be monitored for associated complications.

**Key words:** Chronic hepatitis B; Cirrhosis; Hepatic feature; Liver function; Portal hypertension; Wilson disease

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In Asia, especially China, the incidence of Wilson disease (WD) and its complications is much higher in the younger generation compared to Western societies. This article looks beyond the well-characterized, generalized definition of cirrhosis. It addresses an important but simple question: Can the origin of cirrhosis be classified by clinical features, especially in WD-associated cirrhosis? In this manuscript we define specific clinical characteristics of WD-associated cirrhosis in young patients which are very distinct to those of hepatitis-associated cirrhosis in older patients. These important findings may benefit the clinical diagnosis and ultimate treatment of these younger, vulnerable WD patients.

**Citation:** Zhong HJ, Sun HH, Xue LF, McGowan EM, Chen Y. Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis. *World J Gastroenterol* 2019; 25(3): 378-387

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i3/378.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i3.378

**INTRODUCTION**

Wilson disease (WD), also named hepatolenticular degeneration, is an autosomal recessive disease of copper metabolism caused by mutations in *ATP7B*, which encodes a copper transporting ATPase[1,2]. Dysfunction of this ATPase causes copper overload in the liver, brain, and other organs. Depending on the organs affected, WD has a wide spectrum of clinical symptoms, including hepatic, neurological, psychiatric, and ophthalmological manifestations[2]. As the liver is the primary organ for copper metabolism and has the highest expression level of copper transporting ATPase, hepatic changes are usually the earliest and most frequent manifestations in WD patients[2-4]. Although the prevalence of symptomatic WD is low worldwide (about 1/30000), the frequency of this disease is much higher in the Chinese population (about 5.87/100000)[2,5]. Cirrhosis is a common manifestation in WD patients compared to inpatients with other types of liver diseases[6,7].

Cirrhosis is the 11th most common cause of death globally, accounting for 3.5% of all-cause mortalities[8]. Therefore, it is important to understand the clinical features of cirrhosis for prevention and treatment of these manifestations and complications. A meta-analysis that investigated data from 12 studies estimated that the prevalence of cirrhosis was 34% in WD patients[9]. Clinical symptoms of WD, especially hepatic manifestations, often present in the first decade of life, and most occur between the ages of 5–35[10]. As a result, WD frequently causes cirrhosis in children and young adults[9]. In some areas of Iran and India, WD was found to be the primary cause of cirrhosis in children[11,12]. Generally, cirrhosis is characterized by portal hypertension and hepatic dysfunction, leading to esophageal varices, splenomegaly, ascites, and liver injury[13]. However, cirrhosis caused by WD in children and young adults differs from non-alcoholic fatty liver disease and chronic hepatitis B. As the etiology and onset age of WD-associated cirrhosis are different from those of other kinds of liver cirrhosis, WD-associated cirrhosis may involve a different liver injury pathogenesis. Unfortunately, the hepatic features of cirrhosis in WD patients are less well reported.

Hepatitis B virus (HBV) infection, as the most common chronic viral infection, is the main cause of cirrhosis worldwide[6,13]. Globally, nearly 257 million people are living with HBV, and one third of them live in China[14,15]. About 10%–20% of Chinese patients with chronic hepatitis progress to cirrhosis within 5 years[16], making HBV the leading cause of cirrhosis in the Chinese population[17]. Therefore, we performed this study to delineate the liver features between WD-associated cirrhosis and hepatitis B-associated cirrhosis in the Chinese population.

**MATERIALS AND METHODS**

***Study populations***

In this observational study, we retrospectively reviewed the medical data of consecutive inpatients who were diagnosed with cirrhosis caused by either WD or HBV presenting from January 2010 to August 2018 at the First Affiliated Hospital of Guangdong Pharmaceutical University. The patients were excluded from the study if they met any of the following criteria: (1) Carcinoma; (2) severe heart or pulmonary diseases; (3) fatty liver disease, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, or hepatic parasitic infection; and (4) incomplete medical data. Patients who were hospitalized more than once were recorded only once. This study was performed with the approval of the Ethical Committee of the First Affiliated Hospital of Guangdong Pharmaceutical University. All patients in the study were de-identified.

***Data collection***

The following medical data were extracted from the subjects’ electronic medical records: demographic characteristics, history of smoking and alcohol drinking, medical history (diabetes, hypertension, and liver disease), disease duration, manifestations of cirrhosis, imaging examinations, and laboratory test results including alanine transaminase (ALT), aspartate transaminase (AST), serum albumin (ALB), bilirubin, prothrombin time (PT), total cholesterol (TC), triglyceride, low-density lipoprotein (LDL), high-density lipoprotein, white blood cell (WBC) count, red blood cell (RBC) count, platelet count, procollagen type III N-terminal propeptide (PIIINP), type IV collagen, laminin, and hyaluronic acid.

In addition, disease duration was calculated based on the onset age of WD or HBV infection. Child-Pugh classification was assessed as previously described[18]. Leukopenia was defined as a WBC count < 4.0 × 109/L. Erythropenia was defined as an RBC count < 4.0 × 1012/L for males or 3.5 × 1012/L for females. Thrombocytopenia was defined as a platelet count < 100 × 109/L. The indication for splenectomy was hypersplenism, characterized by splenomegaly, leukopenia, erythropenia, and thrombocytopenia[19]. Smokers were defined as patients who have smoked at some stages in their lifetime. Alcohol consumption was defined when patients drank more than 140g of alcohol per week.

In China, diagnosis of WD is based on the classic criteria: Age of onset; family history; low serum ceruloplasmin (<200 mg/L); elevated urinary copper excretion (≥100 μg/24 h); elevated liver copper (>250 μg/g dry weight); and elevated urinary copper excretion after challenge with 2 × 500 mg D-penicillamine (>1600 μg/24 h)[20]. Chronic hepatitis B was diagnosed based on the clinical manifestations and serological and virological examinations[21].

***Statistical analysis***

The statistical analyses were performed using IBM SPSS statistics software, version 22 (IBM Corp., Armonk, NY, United States). Normally distributed continuous variables are presented as the mean ± standard deviation. Non-normally distributed continuous variables are presented as medians and interquartile ranges. Categorical variables are presented as frequencies and proportions. The statistical significance of the difference in means between the two groups was tested using the unpaired *t*-test. The statistical significance of the difference in medians between the two groups was tested using the Mann–Whitney *U*-test. Categorical variables were tested using the Chi-square test or Fisher’s exact test. To assess the association between cirrhosis etiology and portal vein diameter, and the association between cirrhosis etiology and liver fibrosis markers, multivariable linear regression analysis with a forward stepwise approach was used to adjust for confounders. To assess whether the risk of ascites, splenomegaly, and progression from Child-Pugh grade A to B or C differed between WD-associated cirrhosis patients and hepatitis B-associated cirrhosis patients, logistic regression analysis with a backward stepwise approach was used. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. A *P*-value < 0.05 (two-tailed) was considered statistically significant.

**RESULTS**

***Demographics and clinical characteristics***

Based on the medical data, 56 inpatients with hepatitis B-associated cirrhosis and 60 with WD-associated cirrhosis were enrolled. The mean age and age range of these patients recorded in Table 1 clearly demonstrate that WD-associated cirrhosis was more prevalent in the younger age group, whereas, in general, hepatitis B occurred in older adults. The percentage of males, disease duration, LDL level, and prevalence of diabetes, hypertension, alcohol drinking, and smoking were significantly higher in hepatitis B-associated cirrhosis patients than in WD-associated cirrhosis patients (Table 1). In patients with hepatitis B-associated cirrhosis, 48.21% (27/56) were undergoing treatment with antiviral agents, and 47.06% (24/51) presented with low HBV DNA (≤2000 IU/mL).

***Relationship between cirrhotic etiology and liver fibrosis markers***

The levels of PIIINP, type IV collagen, and hyaluronic acid were lower in WD-associated cirrhosis patients than in hepatitis B-associated cirrhosis patients. However, the level of laminin was higher in WD-associated cirrhosis patients (Table 2). Despite presenting with distinct clinical variations, after adjustment for age, gender, disease duration, diabetes, hypertension, alcohol drinking, and smoking, the multivariable linear regression analysis showed no overt differences in any of the four liver fibrosis markers between the two groups of patients.

***Relationship between cirrhotic etiology and liver function indices***

The PT and the levels of ALT, AST, and bilirubin, but not the level of ALB, were lower in WD-associated cirrhosis patients compared with hepatitis B-associated cirrhosis patients. Additionally, the incidence of hepatic encephalopathy was lower in WD-associated cirrhosis patients. An important observation showed that the percentage of patients with Child-Pugh grades B and C was lower in WD-associated cirrhosis patients compared with hepatitis B-associated cirrhosis patients (Table 3). Logistic regression analysis showed that patients with WD-associated cirrhosis had a significantly decreased risk of progression from Child-Pugh A to B (OR = 0.046, 95% CI: 0.006-0.387, *P* = 0.005), and a non-significant decreased risk for progression to Child-Pugh C (OR = 0.164, 95% CI: 0.013-2.063, *P* = 0.162; Table 4), after adjustment for age, gender, disease duration, diabetes, hypertension, alcohol drinking, and smoking, as compared to patients with hepatitis B-associated cirrhosis.

***Relationship between cirrhotic etiology and features of portal hypertension***

Table 5 shows that the portal vein diameter and incidence of ascites were lower in WD-associated cirrhosis patients than in hepatitis B-associated cirrhosis. However, WD-associated cirrhosis patients had a statistical trend toward a higher incidence of splenomegaly (88.33% *vs* 75.00%, *P* = 0.062). Multivariable linear regression analysis showed that WD-associated cirrhosis was associated with a lower portal vein diameter. Moreover, after adjustment for age, gender, disease duration, diabetes, hypertension, alcohol drinking, smoking, and Child-Pugh classification, the logistic regression analysis showed that WD-associated cirrhosis patients had a significantly decreased risk of ascites compared with hepatitis B-associated cirrhosis patients (OR = 0.08, 95% CI: 0.01-0.48, *P* = 0.005). However, the logistic regression analysis showed that WD-associated cirrhosis patients had a significantly increased risk of splenomegaly compared with hepatitis B-associated cirrhosis patients (OR = 4.15, 95% CI: 1.38-12.45, *P* = 0.011).

***Splenomegaly for hematocytopenia***

Logistic regression analysis showed that splenomegaly was associated with a significantly increased risk of leukopenia (OR = 4.41, 95% CI: 1.29-15.12, *P* = 0.018) and thrombocytopenia (OR = 23.08, 95% CI: 2.86-186.11, *P* = 0.003; Table 6), but not erythropenia. Eight patients with WD-associated cirrhosis and seven with hepatitis B-associated cirrhosis had undergone splenectomy. After splenectomy, 50.00% (4/8) of WD-associated cirrhosis patients and 28.57% (2/7) of hepatitis B-associated cirrhosis patients had a normal WBC count; 62.50% (5/8) and 28.57% (2/7) had a normal platelet count.

**DISCUSSION**

Liver disease is the most common clinical manifestation of WD, and cirrhosis is frequently presented in these patients[4]. WD is not a common disease, and its pathogenesis and early onset of age are quite different from those of other liver diseases[2]. The clinical manifestations of WD are diverse[4], and the clinical features of cirrhosis caused by WD are still unclear. To the best of our knowledge, this is the first study to analyze the liver features of WD-associated cirrhosis and present clear distinct features to distinguish WD-associated cirrhosis from hepatitis B-associated cirrhosis.

In this observational study, compared with patients with hepatitis B-associated cirrhosis, WD-associated cirrhosis presented in a younger age group, and patients developed milder liver dysfunction and portal hypertension manifestations. Consistent with our finding, a recent study involving 1357 WD patients showed that 39.5% of children and adolescents had cirrhosis at diagnosis[22]. As shown in a previous study, the prognosis of WD patients was excellent if the disease was treated appropriately[10]. Nonetheless, patients with WD-associated cirrhosis had a higher risk of splenomegaly, which was found to be a risk factor for leukopenia and thrombocytopenia. In contrast, due to long periods of immune tolerant phases and inactive residual phases, liver injury is more likely to occur at more advanced age in patients with HBV infection[23]. Thus, most patients with HBV infection who progress to cirrhosis do so after the age of 35 years[23].

The degree of liver fibrosis can be reflected by the levels of serum type III collagen, type IV collagen, laminin, and hyaluronic acid, which are components of the extracellular matrix during fibrosis[24,25]. Based on the multivariable linear regression analysis, no significant difference in any of these four markers was found between the two groups of patients. The results showed that the degree of liver fibrosis might be similar between WD-associated cirrhosis and hepatitis B-associated cirrhosis patients. However, these markers do not reflect liver fibrosis directly, and liver biopsy remains the gold standard method for fibrosis assessment. Thus, new diagnostic markers may be needed to assess liver damage and prognosis, and discern WD-associated cirrhosis and hepatitis B-associated cirrhosis treatments.

The liver performs many biochemical functions, such as the synthesis of protein and clotting factors and the metabolism of bilirubin and ammonia[26]. Thus, liver dysfunction, as a feature of cirrhosis, was assessed based on liver injury, synthesis function, metabolism function, and hepatic functional reserve. Compared with WD-associated cirrhosis patients, more severe liver injury was found in hepatitis B-associated cirrhosis patients, based on higher levels of ALT and AST. Moreover, the lower ALB level and longer PT in hepatitis B-associated cirrhosis patients indicated a more serious impairment of synthesis function. It is well known that hepatic encephalopathy, associated with hyperammonemia, is caused by impairment of ammonia detoxification in the liver[27]. Thus, a higher incidence of hepatic encephalopathy and a higher level of bilirubin indicated a more severe impairment of metabolism function in hepatitis B-associated cirrhosis patients. Additionally, the Child-Pugh classification system, a comprehensive index, has been the most widely used model to evaluate liver functional reserve[28]. Our results showed that hepatitis B-associated cirrhosis was a risk factor for progressing from Child-Pugh grade A to B, which indicated that hepatitis B-associated cirrhosis could lead to a more serious impairment of liver functional reserve. Therefore, compared with WD-associated cirrhosis, hepatitis B-associated cirrhosis seemed to cause a more serious impairment of liver function.

Portal hypertension, as another feature of cirrhosis, was assessed based on the portal vein diameter, ascites, and splenomegaly[29,30]. We found that the portal vein diameter was higher in hepatitis B-associated cirrhosis patients than in WD-associated cirrhosis patients. However, a previous study involving 167 healthy children from 1 mo to 15 years old showed that portal vein diameter was correlated with age and height, which means that the wider portal vein diameter in hepatitis B-associated cirrhosis patients might also result from their more advanced age[31]. Thus, a more precise method, such as hepatic venous pressure gradient measurement, was needed to evaluate the portal vein pressure between the two groups of patients[32]. Hepatitis B-associated cirrhosis patients had a higher risk of ascites, which might result from the more serious portal hypertension and lower level of ALB caused by liver dysfunction[33].

Splenomegaly is the most common imaging finding of portal hypertension[30]. A previous study involving 910 cirrhosis patients showed that 50.5% of the patients presented with splenomegaly[34]. Interestingly, the present study showed that the incidence of splenomegaly (88.3%) was not only much higher than the incidence in the previous study, but also than the incidence in hepatitis B-associated cirrhosis patients (75%). In WD, splenomegaly seems to occur frequently, and it can even be the earliest clinical manifestation, particularly in children[10]. Consistent with our finding, previous research estimated that the incidence of splenomegaly is 49.0% (25/51) in WD patients[35], which is higher than that in chronic hepatitis B patients (41.7%; 65/156)[36]. After adjustment for potential confounders, there was a 3.15-fold increased risk of splenomegaly in WD-associated cirrhosis patients compared to hepatitis B-associated cirrhosis patients. There are three possible explanations for these results. First, non-autoimmune hemolytic anemia, which can lead to splenomegaly, has been shown to be common and an onset symptom in 10%–15% of WD patients[37]. Second, high concentration of serum copper might also have toxic effects on the spleen. Third, with increasing age, the size and function of the spleen are easily affected[38], and the younger age among WD-associated cirrhosis patients might also lead to a higher sensitivity of the spleen to all kinds of stimulation.

Additionally, portal hypertension could bring about hypersplenism, which is characterized by splenomegaly and pancytopenia due to excessive portal flow[39]. In this study, we found that splenomegaly was associated with increased risks of leukopenia and thrombocytopenia. As risk factors for certain fatal infections and bleeding (such as spontaneous bacterial peritonitis, urinary tract infection, pneumonia, and esophageal variceal bleeding), leukopenia and thrombocytopenia in WD-associated cirrhosis patients should receive more attention[40]. Regarding hypersplenism treatment, a clinical study in China revealed that splenectomy was a safe and effective therapeutic method for hypersplenism in WD patients, and it demonstrated obvious improvements in WBC and platelet counts in all the patients after splenectomy[19]. Similarly, in our study, most of the WD-associated cirrhosis patients with hypersplenism had normal WBC and platelet counts after splenectomy.

The present study had several limitations. First, as gastroscopy was not performed regularly in the cirrhosis patients, esophageal varices, a typical feature of portal hypertension, could not be compared between the two groups of patients. Second, due to the low economic status of some of the patients and the poor medical services in some areas of China, the patients often received a delayed diagnosis, which might have biased the disease duration assessment. Third, some confounders (such as medication use and duration from onset to diagnosis of disease), which might have had an influence on the results, were not taken into consideration. Finally, the study was a single-center study with a limited sample size. Thus, the results regarding the comparison of hepatic features between WD-associated cirrhosis patients and hepatitis B-associated cirrhosis patients should be interpreted with caution, and large-scale, multi-center studies are needed to confirm these conclusions.

In conclusion, in this study, we provide evidence to show that cirrhosis is not one disease and there is a need for further classification for treatment options. Depending on the origin, cirrhosis presents different clinical features. Our findings, in concurrence with other studies in the literature, show that clinical features occur earlier in WD patients than in chronic hepatitis B patients. An important observation made in this study is that progression from Child-Pugh grade A to B or C differed between WD-associated cirrhosis patients and hepatitis B-associated cirrhosis patients. Notably, WD-associated cirrhosis patients had a higher risk of splenomegaly, which was found to be a risk factor for leukopenia and thrombocytopenia. Based on these findings, it is highly recommended that young Wilson’s disease patients require regular monitoring for blood disorders and infections to alleviate further clinical complications. Additionally, splenectomy might be an effective therapy for hypersplenism in WD-associated cirrhosis patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Cirrhosis is a chronic late stage liver disease associated with hepatitis viruses, alcoholism, and metabolic disorders, such as Wilson disease (WD). As the etiology and onset age of WD-associated cirrhosis are different from those of other kinds of liver cirrhosis, WD-associated cirrhosis may involve a distinct liver injury pathogenesis.

***Research motivation***

We hypothesized that cirrhosis is not one disease and cirrhosis of different etiology may have differential clinical hepatic features.

***Research objectives***

To delineate the liver features between WD-associated cirrhosis and hepatitis B-associated cirrhosis in the Chinese population.

***Research methods***

We performed a cross-sectional study of 60 WD-associated cirrhosis and 56 hepatitis B-associated cirrhosis inpatients. We analyzed the liver fibrosis degree, liver function indices, and portal hypertension features between these two groups.

***Research results***

No inter-group differences were observed in the diagnostic liver fibrosis markers, however, clinical features clearly defined the origin of cirrhosis. Cirrhosis presenting in WD patients had worse liver function, lower incidence of hepatic encephalopathy, and lower portal vein diameter, compared to cirrhosis resulting from hepatitis B. They had decreased risks of progression from Child-Pugh grade A to B and of ascites. Conversely, WD-associated cirrhosis patients had a higher risk of splenomegaly, which was associated with a significantly increased risk of leukopenia and thrombocytopenia.

***Research conclusions***

WD-associated cirrhosis presents a higher risk of splenomegaly associated with leukopenia and thrombocytopenia, although revealing milder liver dysfunction and portal hypertension symptoms. These findings indicated that cirrhosis is not one disease and further classification for diagnosis and treatment options, dependent on origin, are needed.

***Research perspectives***

The higher risk of splenomegaly associated with leucopenia and thrombocytopenia in these younger, vulnerable WD patients with cirrhosis, suggests early and regular monitoring of associated blood disorders and infections to alleviate further clinical complications.

**REFERENCES**

1 **Bandmann O**, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. *Lancet Neurol* 2015; **14**: 103-113 [PMID: 25496901 DOI: 10.1016/S1474-4422(14)70190-5]

2 **Członkowska A**, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, Rybakowski JK, Weiss KH, Schilsky ML. Wilson disease. *Nat Rev Dis Primers* 2018; **4**: 21 [PMID: 30190489 DOI: 10.1038/s41572-018-0018-3]

3 **Asadi Pooya AA**, Eslami NS, Haghighat M. Wilson disease in southern Iran. *Turk J Gastroenterol* 2005; **16**: 71-74 [PMID: 16252195]

4 **Lin LJ**, Wang DX, Ding NN, Lin Y, Jin Y, Zheng CQ. Comprehensive analysis on clinical features of Wilson's disease: an experience over 28 years with 133 cases. *Neurol Res* 2014; **36**: 157-163 [PMID: 24107488 DOI: 10.1179/1743132813Y.0000000262]

5 **Xie JJ**, Wu ZY. Wilson's Disease in China. *Neurosci Bull* 2017; **33**: 323-330 [PMID: 28265897 DOI: 10.1007/s12264-017-0107-4]

6 **Trépo C**, Chan HL, Lok A. Hepatitis B virus infection. *Lancet* 2014; **384**: 2053-2063 [PMID: 24954675 DOI: 10.1016/S0140-6736(14)60220-8]

7 **Marengo A**, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. *Annu Rev Med* 2016; **67**: 103-117 [PMID: 26473416 DOI: 10.1146/annurev-med-090514-013832]

8 **Asrani SK,** Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol* 2019; **70**: 151-171 [PMID: 30266282 DOI: [10.1016/j.jhep.2018.09.014](https://doi.org/10.1016/j.jhep.2018.09.014)]

9 **Roberts EA**, Socha P. Wilson disease in children. *Handb Clin Neurol* 2017; **142**: 141-156 [PMID: 28433098 DOI: 10.1016/B978-0-444-63625-6.00012-4]

10 **Boga S**, Ala A, Schilsky ML. Hepatic features of Wilson disease. *Handb Clin Neurol* 2017; **142**: 91-99 [PMID: 28433114 DOI: 10.1016/B978-0-444-63625-6.00009-4]

11 **Dehghani SM**, Imanieh MH, Haghighat M, Malekpour A, Falizkar Z. Etiology and complications of liver cirrhosis in children:report of a single center from southern Iran. *Middle East J Dig Dis* 2013; **5**: 41-46 [PMID: 24829669]

12 **Simon EG**, Joseph AJ, George B, Zachariah UG, Jeyamani R, Eapen CE, Chandy G, Ramakrishna BS, Kurian G, Chacko A. Aetiology of paediatric portal hypertension - experience of a tertiary care centre in South India. *Trop Doct* 2009; **39**: 42-44 [PMID: 19211426 DOI: 10.1258/td.2008.080050]

13 **Tsochatzis EA**, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet* 2014; **383**: 1749-1761 [PMID: 24480518 DOI: 10.1016/S0140-6736(14)60121-5]

14 **Chen S**, Li J, Wang D, Fung H, Wong LY, Zhao L. The hepatitis B epidemic in China should receive more attention. *Lancet* 2018; **391**: 1572 [PMID: 29695339 DOI: 10.1016/S0140-6736(18)30499-9]

15 **Chen CJ**. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. *Gut* 2018; **67**: 595-598 [PMID: 29367206 DOI: 10.1136/gutjnl-2017-315407]

16 **Liu J**, Fan D. Hepatitis B in China. *Lancet* 2007; **369**: 1582-1583 [PMID: 17499584 DOI: 10.1016/S0140-6736(07)60723-5]

17 **Zhang Y**, Zhang H, Elizabeth A, Liu XQ. Epidemiology of hepatitis B and associated liver diseases in china. *Chin Med Sci J* 2013; **27**: 243-248 [PMID: 23294591 DOI: [10.1016/S1001-9294(13)60009-7](https://doi.org/10.1016/S1001-9294%2813%2960009-7)]

18 **Pugh RN**, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973; **60**: 646-649 [PMID: 4541913 DOI: 10.1002/bjs.1800600817]

19 **Li LY**, Yang WM, Chen HZ, Wu YH, Fang X, Zhang J, Wang Z, Han YS, Wang Y. Successful Splenectomy for Hypersplenism in Wilson's Disease: A Single Center Experience from China. *PLoS One* 2015; **10**: e0124569 [PMID: 25910248 DOI: 10.1371/journal.pone.0124569]

20 **Chinese Society of Neurology.** Guideline of Wilson’s disease diagnosis and treatment. *Zhonghua Shenjingke Zazhi* 2008; **41**: 566-569

21 **Chinese Society of Hepatology, Chinese Medical Association.**; Chinese Society of Infectious Diseases, Chinese Medical Association, Hou JL, lai W. [The guideline of prevention and treatment for chronic hepatitis B: a 2015 update]. *Zhonghua Gan Zang Bing Za Zhi* 2015; **23**: 888-905 [PMID: 26739464 DOI: 10.3760/cma.j.issn.1007-3418.2015.12.002]

22 **Ferenci P**, Stremmel W, Członkowska A, Szalay F, Viveiros A, Stättermayer AF, Bruha R, Houwen R, Pop T, Stauber R, Gschwantler M, Pfeiffenberger J, Yurdaydin C, Aigner E, Steindl-Munda P, Dienes HP, Zoller H, Weiss KH. Age,sex, but not ATP7B genotype effectively influences the clinical phenotype of Wilson disease. *Hepatology* 2018 [PMID: 30232804 DOI: 10.1002/hep.30280]

23 **Liaw YF**, Chu CM. Hepatitis B virus infection. *Lancet* 2009; **373**: 582-592 [PMID: 19217993 DOI: 10.1016/S0140-6736(09)60207-5]

24 **El-Mezayen HA**, Habib S, Marzok HF, Saad MH. Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study. *Eur J Gastroenterol Hepatol* 2015; **27**: 378-385 [PMID: 25874509 DOI: 10.1097/MEG.0000000000000298]

25 **Plevris N,** Sinha R, Hay AW, McDonald N, Plevris JN, Hayes PC. Index serum hyaluronic acid independently and accurately predicts mortality in patients with liver disease. *Aliment Pharmacol Ther* 2018; **48**: 423-430 [PMID: 29971829 DOI: [10.1111/apt.14897](https://doi.org/10.1111/apt.14897)]

26 **He GL**, Feng L, Cai L, Zhou CJ, Cheng Y, Jiang ZS, Pan MX, Gao Y. Artificial liver support in pigs with acetaminophen-induced acute liver failure. *World J Gastroenterol* 2017; **23**: 3262-3268 [PMID: 28566885 DOI: 10.3748/wjg.v23.i18.3262]

27 **Sidhu SS,** Sharma BC, Goyal O, Kishore H, Kaur N. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. *Hepatology* 2017 [PMID: 28749571 DOI: [10.1002/hep.29410](https://doi.org/10.1002/hep.29410)]

28 **Peng Y**, Qi X, Guo X. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. *Medicine* (Baltimore) 2016; **95**: e2877 [PMID: 26937922 DOI: 10.1097/MD.0000000000002877]

29 **Shung DL**, Garcia-Tsao G. Liver Capsule: Portal Hypertension and Varices: Pathogenesis, Stages, and Management. *Hepatology* 2017; **65**: 1038 [PMID: 28032650 DOI: 10.1002/hep.29026]

30 **Nuffer Z**, Marini T, Rupasov A, Kwak S, Bhatt S. The Best Single Measurement for Assessing Splenomegaly in Patients with Cirrhotic Liver Morphology. *Acad Radiol* 2017; **24**: 1510-1516 [PMID: 28800952 DOI: 10.1016/j.acra.2017.06.006]

31 **Soyupak S**, Gunesli A, Seydaoğlu G, Binokay F, Celiktas M, Inal M. Portal venous diameter in children: normal limits according to age, weight and height. *Eur J Radiol* 2010; **75**: 245-247 [PMID: 19409745 DOI: 10.1016/j.ejrad.2009.03.052]

32 **Tseng Y**, Li F, Wang J, Chen S, Jiang W, Shen X, Wu S. Spleen and liver stiffness for noninvasive assessment of portal hypertension in cirrhotic patients with large esophageal varices. *J Clin Ultrasound* 2018; **46**: 442-449 [PMID: 30132919 DOI: 10.1002/jcu.22635]

33 **Adebayo D,** Neong SF, Wong F. Refractory ascites in liver cirrhosis. *Am J Gastroenterol* 2018 [PMID: 29973706 DOI: [10.1038/s41395-018-0185-6](https://doi.org/10.1038/s41395-018-0185-6)]

34 **Orlando R**, Lirussi F, Basso SM, Lumachi F. Splenomegaly as risk factor of liver cirrhosis. A retrospective cohort study of 2,525 patients who underwent laparoscopy. *In Vivo* 2011; **25**: 1009-1012 [PMID: 22021698]

35 **Stremmel W**, Meyerrose KW, Niederau C, Hefter H, Kreuzpaintner G, Strohmeyer G. Wilson disease: clinical presentation, treatment, and survival. *Ann Intern Med* 1991; **115**: 720-726 [PMID: 1929042 DOI: [10.7326/0003-4819-115-9-720](https://doi.org/10.7326/0003-4819-115-9-720)]

36 **Dou J**, Lou Y, Wu J, Lu Y, Jin Y. Thrombocytopenia in patients with hepatitis B virus-related chronic hepatitis: evaluation of the immature platelet fraction. *Platelets* 2014; **25**: 399-404 [PMID: 24047408 DOI: 10.3109/09537104.2013.832742]

37 **Dzieżyc K**, Litwin T, Członkowska A. Other organ involvement and clinical aspects of Wilson disease. *Handb Clin Neurol* 2017; **142**: 157-169 [PMID: 28433099 DOI: 10.1016/B978-0-444-63625-6.00013-6]

38 **Pelizzo G**, Guazzotti M, Klersy C, Nakib G, Costanzo F, Andreatta E, Bassotti G, Calcaterra V. Spleen size evaluation in children: Time to define splenomegaly for pediatric surgeons and pediatricians. *PLoS One* 2018; **13**: e0202741 [PMID: 30138410 DOI: 10.1371/journal.pone.0202741]

39 **Liu Y**, Li J, Jin Y, Zhao L, Zhao F, Feng J, Li A, Wei Y. Splenectomy Leads to Amelioration of Altered Gut Microbiota and Metabolome in Liver Cirrhosis Patients. *Front Microbiol* 2018; **9**: 963 [PMID: 29867867 DOI: 10.3389/fmicb.2018.00963]

40 **Chapin CA**, Bass LM. Cirrhosis and Portal Hypertension in the Pediatric Population. *Clin Liver Dis* 2018; **22**: 735-752 [PMID: 30266160 DOI: 10.1016/j.cld.2018.06.007]

**P-Reviewer:** Kasirga E, KasprzakA, Yan SL **S-Editor:** Yan JP

**L-Editor:** Wang TQ **E-Editor:** Huang Y

**Specialty type:** Gastroenterology and hepatology
**Country of origin:** China
**Peer-review report classification**
**Grade A (Excellent):** 0
**Grade B (Very good):** B
**Grade C (Good):** C, C
**Grade D (Fair):** 0 **Grade E (Poor):** 0

**Table 1 Characteristics of patients with cirrhosis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Wilson disease-associated cirrhosis(*n* = 60) | Hepatitis B-associated cirrhosis(*n* = 56) | *P*-value |
| Age (yr) | 22.00 (16.25-29.75) | 52.00 (45.25-62.00) | <0.001 |
| Male gender | 27 (45.00) | 46 (82.14) | <0.001 |
| Disease duration (years) | 3.00 (1.13-7.00) | 17.50 (3.25-38.25) | <0.001 |
| Diabetes  | 1 (1.67) | 11 (19.64) | 0.001 |
| Hypertension  | 0 (0) | 13 (23.21) | <0.001 |
| Alcohol drinking | 0 (0) | 12 (21.42) | <0.001 |
| Smoking | 2 (3.33) | 13 (23.21) | 0.001 |
| TC (mmol/L) | 4.22 (3.67-4.67)(*n* = 39) | 4.10 (2.71-4.67)(*n* = 39) | 0.327 |
| TG (mmol/L) | 0.94 (0.70-1.37)(*n* = 39) | 0.99 (0.65-1.60)(*n* = 39) | 0.853 |
| HDL (mmol/L) | 1.40 ± 0.30(*n* = 39) | 1.16 ± 0.32(*n* = 39) | 0.786 |
| LDL (mmol/L) | 2.17 ± 0.61(*n* = 39) | 2.28 ± 0.91(*n* = 39) | 0.014 |

Data are presented as medians (interquartile ranges) or *n* (%). HDL: high-density lipoprotein; LDL: low-density lipoprotein; TC: total cholesterol; TG: triacylglycerol.

**Table 2 Relationship between cirrhotic etiology and liver fibrosis markers**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Wilson disease-associated cirrhosis(*n* = 60) | Hepatitis B-associated cirrhosis(*n* = 53) | *P*-value |
| Type IV collagen (ng/mL) | 61.55 (52.18-72.11) | 79.48 (63.16-107.56) | <0.001 |
| PIIINP (μg/mL) | 79.92(54.68-122.65) | 109.16 (70.24-155.30) | 0.019 |
| Laminin (ng/mL) | 104.09 (92.80-118.21) | 96.27 (70.08-116.02) | 0.013 |
| Hyaluronic acid (ng/mL) | 75.12 (39.27-131.98) | 193.16 (74.77-625.90) | <0.001 |

Data are presented as medians (interquartile ranges). PIIINP: procollagen type III N-terminal propeptide.

**Table 3 Relationship between cirrhotic etiology and liver function indices**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Wilson disease-associated cirrhosis(*n* = 60) | Hepatitis B-associated cirrhosis(*n* = 56) | *P*-value |
| ALT (U/L) | 23.00 (17.00-34.75) | 33.50 (19.33-81.25) | 0.002 |
| AST (U/L) | 25.00 (19.00-40.00) | 41.50 (27.25-96.50) | <0.001 |
| Albumin (g/L) | 40.00 (37.00-43.00) | 33.00 (29.25-39.75) | <0.001 |
| PT (s) | 14.05 (13.43-14.78) | 15.50 (13.93-18.18) | 0.003 |
| Bilirubin (μmol/L) | 12.40 (8.55-18.38) | 21.70 (12.73-41.08) | <0.001 |
| Hepatic encephalopathy | 0 (0) | 3 (5.36) | 0.109 |
| Child-Pugh classification |  |  | <0.001 |
|  A | 54 (90.00) | 24 (42.86) |  |
|  B | 4 (6.67) | 24 (42.86) |  |
|  C | 2 (3.33) | 8 (14.29) |  |

Data are presented as medians (interquartile ranges) or N (%). ALT: alanine transferase; AST: aspartate transaminase; PT: prothrombin time.

**Table 4** **Logistic regression analysis of Child-Pugh classification in patients with Wilson disease-associated cirrhosis *vs* patients with hepatitis B-associated cirrhosis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | OR | 95% CI | *P*-value |
| Child-Pugh classification |  |  |  |
|  A | Ref. | - | - |
|  B | 0.046 | 0.006-0.387 | 0.005 |
|  C | 0.164 | 0.013-2.063 | 0.162 |

Data were adjusted for age, gender, disease duration, diabetes, hypertension, alcohol drinking, and smoking. CI: confidence interval; OR: odds ratio; Ref: reference.

**Table 5** **Relationship between cirrhotic etiology and features of portal hypertension**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Wilson disease-associated cirrhosis(*n* = 60) | Hepatitis B-associated cirrhosis(*n* = 56) | *P*-value |
| Portal vein diameter (mm) | 10.00 (8.00-10.00) | 14.00 (12.00-16.00) | <0.001 |
| Ascites | 2 (3.33) | 24 (42.86) | <0.001 |
| Splenomegaly/splenectomy | 53 (88.33) | 42 (75.00) | 0.062 |

Data are presented as medians (interquartile ranges) or *n* (%).

**Table 6** **Logistic regression analysis of risk of hematocytopenia due to splenomegaly**

|  |  |  |  |
| --- | --- | --- | --- |
|  | OR | 95%CI | *P*-value |
| Leucopenia | 4.41 | 1.29-15.12 | 0.018 |
| Erythropenia | - | - | - |
| Thrombocytopenia | 23.08 | 2.86-186.11 | 0.003 |

Data were adjusted for age, gender, disease duration, diabetes, hypertension, alcohol drinking, smoking, and Child-Pugh classification. CI: confidence interval; OR: odds ratio.